Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877)
:1877
Want to see HK:1877 full AI Analyst Report?
1877 Stock Chart & Stats
HK$27.54
-HK$0.08(-0.74%)
At close: 4:00 PM EST
HK$27.54
-HK$0.08(-0.74%)
Day’s Range― - ―
52-Week RangeHK$14.10 - HK$38.64
Previous CloseN/A
Volume306.00K
Average Volume (3M)7.63M
Market Cap
HK$41.62B
Enterprise ValueHK$41.56B
Total Cash (Recent Filing)HK$3.22B
Total Debt (Recent Filing)HK$4.14B
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Apr 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding260,295,700
10 Day Avg. Volume5,398,960
30 Day Avg. Volume7,633,399
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)3.19
Price to Sales (P/S)7.92
P/FCF Ratio-15.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$32.45Price Target Upside17.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.45
Revenue Forecast (FY)HK$3.31B
Bulls Say, Bears Say
Bulls Say
Integrated Value ChainJunshi’s integrated model — discovery through commercialization — creates durable operational advantages: tighter clinical-to-commercial feedback loops, ownership of manufacturing and launch execution, and multiple potential revenue levers (sales, licensing, contract income). This reduces reliance on single partners and supports sustained product franchise building over the next several quarters.
Biologics / Monoclonal Antibody PortfolioFocus on biologics, particularly monoclonal antibodies in oncology and immune diseases, aligns with long-term structural demand and high technical barriers to entry. Such assets typically offer durable pricing power, longer product life cycles and partnership/licensing optionality that can underpin revenue and strategic collaboration prospects over multiple quarters.
Equity-supported Balance SheetA sizable equity base provides a cushion to absorb R&D losses and operational volatility, improving resilience versus highly leveraged peers. This structural capital support increases the company’s ability to access financing or pursue partnerships without immediate solvency pressure, preserving strategic optionality over the medium term.
Bears Say
Persistent Negative Cash GenerationConsistent negative operating and free cash flow is a durable constraint: ongoing cash burn forces reliance on external funding, increasing dilution or debt financing risk. This limits the company’s ability to self-fund late-stage trials, marketing rollouts, or manufacturing scale-ups, raising execution and financing risks over the next several quarters.
Volatile Revenue And Persistent LossesLarge year-to-year revenue swings and sustained net losses reduce predictability of cash flows and weaken long-term margin sustainability. This volatility complicates forecasting, undermines negotiating leverage with payers/partners, and heightens dependency on milestone/licensing events to stabilize finances across the next 2–6 months.
Rising Leverage And Financing RelianceRapidly increasing debt raises refinancing and interest burden risks at a time of negative cash flow. Higher leverage narrows financial flexibility, may crowd out R&D investment or force unfavorable financing terms, and amplifies solvency sensitivity to any further revenue setbacks over the medium term.
Shanghai Junshi Biosciences Co., Ltd. Class H News
1877 FAQ
What was Shanghai Junshi Biosciences Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Junshi Biosciences Co., Ltd. Class H lowest stock price was HK$14.10 and its highest was HK$38.64 in the past 12 months.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s market cap?
Shanghai Junshi Biosciences Co., Ltd. Class H’s market cap is HK$41.62B.
When is Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date is Apr 27, 2026 which is today.
How were Shanghai Junshi Biosciences Co., Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Shanghai Junshi Biosciences Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Junshi Biosciences Co., Ltd. Class H’s price is currently Undervalued.
Does Shanghai Junshi Biosciences Co., Ltd. Class H pay dividends?
Shanghai Junshi Biosciences Co., Ltd. Class H does not currently pay dividends.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate?
Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Junshi Biosciences Co., Ltd. Class H have?
Shanghai Junshi Biosciences Co., Ltd. Class H has 260,295,700 shares outstanding.
What happened to Shanghai Junshi Biosciences Co., Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shanghai Junshi Biosciences Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:1877
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Junshi Biosciences Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$32.45 (17.83% Upside)
HK$32.45 (17.83% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.67%
12-Months-Change
Fundamentals
Return on Equity
-14.44%
Trailing 12-Months
Asset Growth
20.20%
Trailing 12-Months
Company Description
Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
1877 Stock 12 Month Forecast
Average Price Target
HK$32.45
▲(17.83% Upside)
Technical Analysis
Zai Lab Ltd
―
Alphamab Oncology
―
RemeGen Co. Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---